MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
- Gained alignment with U.S. Food and Drug Administration (FDA) on the ongoing Phase 2 AQUAx2 randomized double-blind, placebo-controlled pivotal study in Grade 2/3 radiation-induced xerostomia (R...
What are the key milestones and risk factors that could cause the data readout to be delayed or the trial to fail?
How might the FDA alignment impact the timing of any partnership or licensing negotiations with larger pharmaceutical firms?
What is the anticipated cash burn rate through the end of 2026, and will the company need additional financing to fund the trial?
11 days ago